Serving Patients Nationwide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By mimicking these naturally occurring hormones, the medication helps regulate blood sugar levels and slows the digestive process. This biological shift significantly reduces appetite and increases feelings of satiety after eating.
Adults between the ages of 18 and 74.
Individuals with a Body Mass Index (BMI) of 25 or higher.
Those seeking a non-surgical solution for long-term weight management.
Patients without a history of severe gastrointestinal or kidney conditions.
Patients often experience a significant reduction in food cravings and improved control over caloric intake. This clinical approach supports a steady weight loss rate of one to two pounds per week when combined with lifestyle adjustments. Beyond weight reduction, the treatment promotes metabolic health and sustained energy levels throughout the day.
B12-MIC injections for metabolic and energy support.
Semaglutide Injections for GLP-1 therapy.
Serving Patients Nationwide
In the News
Enough Is Enough.
It’s Time For a Solution
That Works
Find out what
can do for you.
